Future Fields
+38%
est. 2Y upside i
We make unmakeable proteins with radical advanced biomanufacturing.
Rank
#1684
Sector
Biotechnology
Est. Liquidity
~5Y
Data Quality
Data: LowFuture Fields offers a strong moat and large TAM, but the lack of revenue data and high preference overhang create significant risk for a 2-year horizon.
Last updated: July 3, 2026
IPO window opens or acquisition by pharma within 2 years due to strong proprietary platform. Valuation reaches 5x entry ($150M) but diluted 20%.
Steady adoption with contract manufacturing revenue; valuation doubles to $60M despite dilution from a follow-on round.
Incumbent competition and failure to scale lead to zero recovery; common stock worthless after preference liquidation of $21.5M.
Preference Stack Risk
severeFunding Intensity
7170%Total funding of $21.5M against estimated $30M entry valuation gives ~72% preference overhang, severely diluting common upside.
Dilution Risk
highAs an early-stage biotech, future financings are likely within 2 years, potentially diluting existing equity by 20% or more.
Secondary Liquidity
noneNo secondary market activity reported; liquidity likely tied to exit event.
Questions to Ask at the Interview
Strategic questions based on Future Fields's data — designed to show you've done your homework.
- 1
“How do you plan to achieve commercial scale and compete with established biomanufacturing platforms?”
- 2
“What is the current revenue traction and path to profitability?”
- 3
“What is the typical timeline to liquidity, and how does the preference stack affect common equity value?”
Community
Valuation Sentiment
Our model estimates +38% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.